Iradimed (NASDAQ:IRMD) Releases Earnings Results, Misses Expectations By $0.05 EPS

Iradimed (NASDAQ:IRMD) issued its quarterly earnings data on Thursday. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.05), Zacks reports. Iradimed had a net margin of 26.12% and a return on equity of 23.99%. Iradimed updated its Q1 2025 guidance to 0.390-0.430 EPS and its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Stock Performance

NASDAQ:IRMD opened at $55.23 on Friday. The stock has a 50-day simple moving average of $57.20 and a 200-day simple moving average of $52.10. The stock has a market cap of $699.76 million, a P/E ratio of 37.83 and a beta of 0.82. Iradimed has a 1 year low of $40.18 and a 1 year high of $63.29.

Iradimed Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 5th. Investors of record on Monday, February 24th will be paid a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 1.23%. This is a boost from Iradimed’s previous quarterly dividend of $0.15. The ex-dividend date is Monday, February 24th. Iradimed’s payout ratio is presently 41.10%.

Analyst Upgrades and Downgrades

IRMD has been the subject of several analyst reports. StockNews.com cut Iradimed from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Roth Mkm reissued a “buy” rating and set a $72.00 target price (up from $60.00) on shares of Iradimed in a research note on Friday.

Insider Transactions at Iradimed

In other news, CFO John Glenn sold 2,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the transaction, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.